MAdd image
Mazdutide
Weight LossSingleA dual GLP-1 / glucagon receptor agonist developed in China, studied for weight loss and type-2 diabetes.
Half-life
120 h
Common dose
1.5 – 9 mg
Dosing frequency
Weekly
Administration
Subcutaneous
How it works
Mazdutide combines GLP-1 satiety effects with glucagon-mediated energy expenditure, similar in concept to retatrutide minus the GIP component.
Protocol notes
Trial titration: 1.5–3 mg weekly up to 9 mg weekly over months. Slow titration for tolerance.
Reported side effects
GI effects similar to other GLP-1s — nausea, diarrhea, decreased appetite.